ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02201849
Recruitment Status : Completed
First Posted : July 28, 2014
Last Update Posted : January 13, 2015
Sponsor:
Information provided by (Responsible Party):
Alkermes, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: Study Drug Drug: Active Control Drug: Placebo Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
Study Start Date : July 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Study Drug
Oral capsules
 Drug: Study Drug
Other Name: ALKS 8700 capsules
Active Comparator: Active Control
Oral capsules
 Drug: Active Control
Other Name: TECFIDERA® capsules
Placebo Comparator: Placebo
Oral capsules
 Drug: Placebo
Other Name: Placebo capsules


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and tolerability will be measured by incidence of adverse events [ Time Frame: up to 27 days ]

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) [ Time Frame: up to 27 days ]
    Concentrations will be measured predose and at 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose

  2. Time to attain Cmax (Tmax) [ Time Frame: Up to 27 days ]
  3. Area under the concentration-time curve from 0 to the last quantifiable time interval (AUClast) [ Time Frame: Up to 27 days ]
  4. Area under the concentration-time curve from time 0 to infinity (AUCinf) [ Time Frame: Up to 27 days ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Has a body-mass Index (BMI) >/=18.0 and </=32.0 kg/m2
  • Agrees to use an acceptable method of contraception for the duration of the study and for 30 days after any study drug administration
  • Additional criteria may apply

Exclusion Criteria:

  • Is currently pregnant or breastfeeding
  • Has a lifetime history of menopausal hot flashes
  • Has a clinically significant medical condition
  • Has had a clinically significant illness in the 30 days prior to first study drug administration
  • Has had a serious infection (eg, pneumonia or septicemia) within the 3 months prior to study drug administration
  • Has had any vaccinations in the 4 weeks prior to inpatient admission
  • Has a lifetime history of diabetes
  • Additional criteria may apply
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02201849


Locations
United States, Texas
Alkermes Investigational Site
Austin, Texas, United States
Sponsors and Collaborators
Alkermes, Inc.
Investigators
Study Director: Richard Leigh-Pemberton, MD Alkermes, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Alkermes, Inc.
ClinicalTrials.gov Identifier: NCT02201849     History of Changes
Other Study ID Numbers: ALK8700-001
First Posted: July 28, 2014    Key Record Dates
Last Update Posted: January 13, 2015
Last Verified: January 2015

Keywords provided by Alkermes, Inc.:
Alkermes
ALKS 8700

Additional relevant MeSH terms:
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
 Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases